127 related articles for article (PubMed ID: 38891954)
1. Development of a Biosafety Level 1 Cellular Assay for Identifying Small-Molecule Antivirals Targeting the Main Protease of SARS-CoV-2: Evaluation of Cellular Activity of GC376, Boceprevir, Carmofur, Ebselen, and Selenoneine.
Fukumoto Y; Suzuki N; Hara R; Tanaka YK; Ogra Y
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891954
[TBL] [Abstract][Full Text] [Related]
2. The Mpro structure-based modifications of ebselen derivatives for improved antiviral activity against SARS-CoV-2 virus.
Qiao Z; Wei N; Jin L; Zhang H; Luo J; Zhang Y; Wang K
Bioorg Chem; 2021 Dec; 117():105455. PubMed ID: 34740055
[TBL] [Abstract][Full Text] [Related]
3. In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.
Nogara PA; Omage FB; Bolzan GR; Delgado CP; Aschner M; Orian L; Teixeira Rocha JB
Mol Inform; 2021 Aug; 40(8):e2100028. PubMed ID: 34018687
[TBL] [Abstract][Full Text] [Related]
4. Structure-Activity Studies Reveal Scope for Optimisation of Ebselen-Type Inhibition of SARS-CoV-2 Main Protease.
Thun-Hohenstein STD; Suits TF; Malla TR; Tumber A; Brewitz L; Choudhry H; Salah E; Schofield CJ
ChemMedChem; 2022 Feb; 17(4):e202100582. PubMed ID: 34850566
[TBL] [Abstract][Full Text] [Related]
5. Glycyrrhizic acid conjugates with amino acid methyl esters target the main protease, exhibiting antiviral activity against wild-type and nirmatrelvir-resistant SARS-CoV-2 variants.
Le UNP; Chang YJ; Lu CH; Chen Y; Su WC; Chao ST; Baltina LA; Petrova SF; Li SR; Hung MC; Lai MMC; Baltina LA; Lin CW
Antiviral Res; 2024 Jul; 227():105920. PubMed ID: 38821317
[TBL] [Abstract][Full Text] [Related]
6. The Se-S Bond Formation in the Covalent Inhibition Mechanism of SARS-CoV-2 Main Protease by Ebselen-like Inhibitors: A Computational Study.
Parise A; Romeo I; Russo N; Marino T
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575955
[TBL] [Abstract][Full Text] [Related]
7. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.
Yuda GPWC; Hanif N; Hermawan A
Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683
[TBL] [Abstract][Full Text] [Related]
8. Differing pan-coronavirus antiviral potency of boceprevir and GC376 in vitro despite discordant molecular docking predictions.
Wang Y; Li P; Lavrijsen M; Li Y; Ma Z; Peppelenbosch MP; Baig MS; Pan Q
Arch Virol; 2022 Apr; 167(4):1125-1130. PubMed ID: 35171357
[TBL] [Abstract][Full Text] [Related]
9. N-Terminal Finger Stabilizes the S1 Pocket for the Reversible Feline Drug GC376 in the SARS-CoV-2 M
Arutyunova E; Khan MB; Fischer C; Lu J; Lamer T; Vuong W; van Belkum MJ; McKay RT; Tyrrell DL; Vederas JC; Young HS; Lemieux MJ
J Mol Biol; 2021 Jun; 433(13):167003. PubMed ID: 33895266
[TBL] [Abstract][Full Text] [Related]
10. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives.
Amporndanai K; Meng X; Shang W; Jin Z; Rogers M; Zhao Y; Rao Z; Liu ZJ; Yang H; Zhang L; O'Neill PM; Samar Hasnain S
Nat Commun; 2021 May; 12(1):3061. PubMed ID: 34031399
[TBL] [Abstract][Full Text] [Related]
11. A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition.
Dey-Rao R; Smith GR; Timilsina U; Falls Z; Samudrala R; Stavrou S; Melendy T
Antiviral Res; 2021 Nov; 195():105183. PubMed ID: 34626674
[TBL] [Abstract][Full Text] [Related]
12. Site mapping and small molecule blind docking reveal a possible target site on the SARS-CoV-2 main protease dimer interface.
Liang J; Karagiannis C; Pitsillou E; Darmawan KK; Ng K; Hung A; Karagiannis TC
Comput Biol Chem; 2020 Dec; 89():107372. PubMed ID: 32911432
[TBL] [Abstract][Full Text] [Related]
13. In silico screening of potential inhibitors from Cordyceps species against SARS-CoV-2 main protease.
Deshmukh N; Talkal R; Lakshmi B
J Biomol Struct Dyn; 2024 Jun; 42(9):4395-4411. PubMed ID: 37325819
[TBL] [Abstract][Full Text] [Related]
14. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
Kitamura N; Sacco MD; Ma C; Hu Y; Townsend JA; Meng X; Zhang F; Zhang X; Ba M; Szeto T; Kukuljac A; Marty MT; Schultz D; Cherry S; Xiang Y; Chen Y; Wang J
J Med Chem; 2022 Feb; 65(4):2848-2865. PubMed ID: 33891389
[TBL] [Abstract][Full Text] [Related]
15. Conserved interactions required for inhibition of the main protease of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Shitrit A; Zaidman D; Kalid O; Bloch I; Doron D; Yarnizky T; Buch I; Segev I; Ben-Zeev E; Segev E; Kobiler O
Sci Rep; 2020 Nov; 10(1):20808. PubMed ID: 33257760
[TBL] [Abstract][Full Text] [Related]
16. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study.
Baig MH; Sharma T; Ahmad I; Abohashrh M; Alam MM; Dong JJ
Molecules; 2021 Mar; 26(6):. PubMed ID: 33802860
[TBL] [Abstract][Full Text] [Related]
17. Machine learning combines atomistic simulations to predict SARS-CoV-2 Mpro inhibitors from natural compounds.
Nguyen TH; Thai QM; Pham MQ; Minh PTH; Phung HTT
Mol Divers; 2024 Apr; 28(2):553-561. PubMed ID: 36823394
[TBL] [Abstract][Full Text] [Related]
18. Depicting the inhibitory potential of polyphenols from
Ghosh R; Chakraborty A; Biswas A; Chowdhuri S
J Biomol Struct Dyn; 2022 Jun; 40(9):4110-4121. PubMed ID: 33292085
[TBL] [Abstract][Full Text] [Related]
19. Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19.
Joshi T; Sharma P; Joshi T; Pundir H; Mathpal S; Chandra S
Mol Divers; 2021 Aug; 25(3):1665-1677. PubMed ID: 32602074
[TBL] [Abstract][Full Text] [Related]
20. A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation.
Rakib A; Nain Z; Sami SA; Mahmud S; Islam A; Ahmed S; Siddiqui ABF; Babu SMOF; Hossain P; Shahriar A; Nainu F; Emran TB; Simal-Gandara J
Brief Bioinform; 2021 Mar; 22(2):1476-1498. PubMed ID: 33623995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
